FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285401642> ?p ?o ?g. }

• W4285401642 endingPage "861" @default.
• W4285401642 startingPage "856" @default.
• W4285401642 abstract "A subset of patients with oligometastatic cancer experience early widespread cancer dissemination and do not benefit from metastasis-directed therapy such as SABR. This study aimed to identify factors associated with early polymetastatic relapse (PMR).The SABR-5 trial was a single arm phase 2 study conducted at all 6 regional cancer centers across British Columbia (BC), Canada. SABR for oligometastases was only offered on trial. Patients with up to 5 oligometastatic lesions (total, progressing, or induced) received SABR to all lesions. Patients were 18 years of age or older, Eastern Cooperative Oncology Group 0 to 2 and life expectancy ≥6 months. This secondary analysis evaluated factors associated with early PMR, defined as disease recurrence within 6 months of SABR, which is not amenable to further local treatment. Univariable and multivariable analyses were performed using binary logistic regression. The Kaplan-Meier method and log-rank tests assessed PMR-free survival and differences between risk groups, respectively.Between November 2016 and July 2020, 381 patients underwent treatment on SABR-5. A total of 16% of patients experienced PMR. Worse performance status (Eastern Cooperative Oncology Group 1-2 vs 0; hazard ratio [HR] = 2.01, P = .018), nonprostate/breast histology (HR = 3.64, P <.001), and oligoprogression (HR = 3.84, P <.001) were independent predictors for early PMR. Risk groups were identified with median PMR-free survival ranging from 5 months to not yet reached at the time of analysis. Rates of 3-year overall survival were 0%, 53% (95% confidence interval [CI], 48-58), 77% (95% CI, 73-81), and 93% (95% CI, 90-96) in groups 1 to 4, respectively (P <.001).Four distinct risk groups for early PMR are identified, which differ significantly in PMR-free survival and overall survival. The group with all 3 risk factors had a median PMR-free survival of 5 months and may not benefit from local ablative therapy alone. This model should be externally validated with data from other prospective trials." @default.
• W4285401642 created "2022-07-14" @default.
• W4285401642 creator A5002159135 @default.
• W4285401642 creator A5011629900 @default.
• W4285401642 creator A5015170140 @default.
• W4285401642 creator A5031291680 @default.
• W4285401642 creator A5032966821 @default.
• W4285401642 creator A5037427247 @default.
• W4285401642 creator A5040003025 @default.
• W4285401642 creator A5050537425 @default.
• W4285401642 creator A5051361037 @default.
• W4285401642 creator A5059063501 @default.
• W4285401642 creator A5066295884 @default.
• W4285401642 creator A5068626181 @default.
• W4285401642 creator A5081144378 @default.
• W4285401642 creator A5086379823 @default.
• W4285401642 creator A5090401347 @default.
• W4285401642 date "2022-12-01" @default.
• W4285401642 modified "2023-09-27" @default.
• W4285401642 title "Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial" @default.
• W4285401642 cites W2031688279 @default.
• W4285401642 cites W2160166879 @default.
• W4285401642 cites W2767597469 @default.
• W4285401642 cites W2769565484 @default.
• W4285401642 cites W2801911503 @default.
• W4285401642 cites W2895716286 @default.
• W4285401642 cites W2939770857 @default.
• W4285401642 cites W2982490039 @default.
• W4285401642 cites W2997721110 @default.
• W4285401642 cites W3104612125 @default.
• W4285401642 cites W3150214063 @default.
• W4285401642 cites W4232184817 @default.
• W4285401642 cites W4241696369 @default.
• W4285401642 cites W4297964923 @default.
• W4285401642 doi "https://doi.org/10.1016/j.ijrobp.2022.06.094" @default.
• W4285401642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35840110" @default.
• W4285401642 hasPublicationYear "2022" @default.
• W4285401642 type Work @default.
• W4285401642 citedByCount "2" @default.
• W4285401642 countsByYear W42854016422023 @default.
• W4285401642 crossrefType "journal-article" @default.
• W4285401642 hasAuthorship W4285401642A5002159135 @default.
• W4285401642 hasAuthorship W4285401642A5011629900 @default.
• W4285401642 hasAuthorship W4285401642A5015170140 @default.
• W4285401642 hasAuthorship W4285401642A5031291680 @default.
• W4285401642 hasAuthorship W4285401642A5032966821 @default.
• W4285401642 hasAuthorship W4285401642A5037427247 @default.
• W4285401642 hasAuthorship W4285401642A5040003025 @default.
• W4285401642 hasAuthorship W4285401642A5050537425 @default.
• W4285401642 hasAuthorship W4285401642A5051361037 @default.
• W4285401642 hasAuthorship W4285401642A5059063501 @default.
• W4285401642 hasAuthorship W4285401642A5066295884 @default.
• W4285401642 hasAuthorship W4285401642A5068626181 @default.
• W4285401642 hasAuthorship W4285401642A5081144378 @default.
• W4285401642 hasAuthorship W4285401642A5086379823 @default.
• W4285401642 hasAuthorship W4285401642A5090401347 @default.
• W4285401642 hasConcept C106159729 @default.
• W4285401642 hasConcept C126322002 @default.
• W4285401642 hasConcept C143998085 @default.
• W4285401642 hasConcept C151956035 @default.
• W4285401642 hasConcept C162324750 @default.
• W4285401642 hasConcept C187625094 @default.
• W4285401642 hasConcept C207103383 @default.
• W4285401642 hasConcept C44249647 @default.
• W4285401642 hasConcept C509974204 @default.
• W4285401642 hasConcept C71924100 @default.
• W4285401642 hasConcept C85393063 @default.
• W4285401642 hasConcept C91602232 @default.
• W4285401642 hasConceptScore W4285401642C106159729 @default.
• W4285401642 hasConceptScore W4285401642C126322002 @default.
• W4285401642 hasConceptScore W4285401642C143998085 @default.
• W4285401642 hasConceptScore W4285401642C151956035 @default.
• W4285401642 hasConceptScore W4285401642C162324750 @default.
• W4285401642 hasConceptScore W4285401642C187625094 @default.
• W4285401642 hasConceptScore W4285401642C207103383 @default.
• W4285401642 hasConceptScore W4285401642C44249647 @default.
• W4285401642 hasConceptScore W4285401642C509974204 @default.
• W4285401642 hasConceptScore W4285401642C71924100 @default.
• W4285401642 hasConceptScore W4285401642C85393063 @default.
• W4285401642 hasConceptScore W4285401642C91602232 @default.
• W4285401642 hasIssue "5" @default.
• W4285401642 hasLocation W42854016421 @default.
• W4285401642 hasLocation W42854016422 @default.
• W4285401642 hasOpenAccess W4285401642 @default.
• W4285401642 hasPrimaryLocation W42854016421 @default.
• W4285401642 hasRelatedWork W1900595920 @default.
• W4285401642 hasRelatedWork W2114624491 @default.
• W4285401642 hasRelatedWork W2154948599 @default.
• W4285401642 hasRelatedWork W2194631636 @default.
• W4285401642 hasRelatedWork W2384708512 @default.
• W4285401642 hasRelatedWork W2793335702 @default.
• W4285401642 hasRelatedWork W2889691785 @default.
• W4285401642 hasRelatedWork W2897723160 @default.
• W4285401642 hasRelatedWork W2985214450 @default.
• W4285401642 hasRelatedWork W4210646467 @default.
• W4285401642 hasVolume "114" @default.
• W4285401642 isParatext "false" @default.
• W4285401642 isRetracted "false" @default.

• next